Recurrence of Bladder Cancer After Transurethral Resection With Hexvix.

Trial Profile

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Hexyl aminolevulinate (Primary) ; Mitomycin
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors GE Healthcare
  • Most Recent Events

    • 10 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 22 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top